- Sanofi to acquire Synthorx for $2.5 B
- AI biotech firm Zenerchi to penetrate within Asia
- GE Healthcare to personalise tissue regeneration
- AstraZeneca receives Chinese marketing nod for Lynparza
- Dubai Health Authority signs MoU with VPS Healthcare
- Hitachi to provide CNAO with Proton Therapy System
- BC Platforms to expand Genotyping services across Europe
- BitBiome to analyse gut bacteria related to cancer
- Amazon Web Services collaborates with Novartis
- HEC Pharm, Biocon, Sun Pharma get FDA approval for MS drug
- Biocon to unlock affordable access to insulins globally
- DHA Chief inaugurates multiorgan transplant centre in India
- Hummingbird Bio raises $19M in Series B round
- Eppendorf with new CEO dual leadership
-
Singapore | 04 July 2019 | News
Latest technologies to transform healthcare
A new consortium led by the Institute for Health Innovation and Technology (iHealthtech) at NUS will tap on th...Read more
Europe | 05 November 2019 | Influencers
TPP Commits To Transform The Delivery of Health and Care Globally
Nov Special Interview - Malaysia. TPP is a healthcare technology company, dedicated to delivering world...Read more
-
World | 09 December 2019 | News
Sanofi to acquire Synthorx for $2.5 B
Sanofi and Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of p...Read more
-
China | 09 December 2019 | News
AI biotech firm Zenerchi to penetrate within Asia
Life extension and biomedical simulation and visualization AI company US based Zenerchi and China ba...Read more
-
Middle East countries | 16 July 2019 | News
Filterlex Medical raises $3M in Series A Financing
Filterlex Medical is a medical device start-up company based in Israel, developing an innovative embolic ...Read more
-
Thailand | 30 July 2019 | News
Thai startups to capture a major chunk of healthcare market
The medical device market in ASEAN is predicted to be worth US$8.5 billion by 2021, and Thai entrepreneurs wan...Read more
Needs much more for world without diabetes
Diabetes is on the rise across the globe as reported in the most recent 8th edition of the International Diabetes Federation (IDF) Diabetes Atlas 2017. As Diabetes is a lifestyle disease, it can be prevented by adopting appropriate lifestyle. This is what the evidence from studies conducted in the USA, Finland, China, India and Japan have proved. However, the pharma industry has been investing on R&D and launching new products but needs much more. From January 2019 to October 31, 2019, the US FDA has approved three products for type 2 diabetes (two drugs Rybelsus and Victoza from Novo Nordisk and one drug – Farxiga from AstraZeneca).
